EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles

Mirjam Stahl iD, Martha Dohna, Simon Y Graeber iD, Olaf Sommerburg iD, Diane M Renz, Sophia T Pallenberg, Andreas Voskrebenzev, Katharina Schütz iD, Gesine Hansen, Felix Doellinger, Eva Steinke, Stephanie Thee iD und 11 weitere

European Respiratory Journal · 2024-09 · 64 (3) · 2400004

DOI: 10.1183/13993003.00004-2024 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Respiratory Journal, online erschienen am 20.06.2024. Verfasst von Mirjam Stahl und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Magnetic Resonance Imaging, Aminophenols, Quinolones. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Federal Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We recently demonstrated that elexacaftor/tezacaftor/ivacaftor (ETI) improves the lung clearance index (LCI) and abnormalities in lung morphology detected by magnetic resonance imaging (MRI) in adolescent and adult patients with cystic fibrosis (CF). However, real-world data on the effect of ETI on these sensitive outcomes of lung structure and function in school-age children with CF have not been reported. The aim of this study was therefore to examine the effect of ETI on the LCI and the lung MRI score in children aged 6–11 years with CF and one or two F508del alleles.

Methods

This prospective, observational, multicentre, post-approval study assessed the longitudinal LCI up to 12 months and the lung MRI score before and 3 months after initiation of ETI.

Results

A total of 107 children with CF including 40 heterozygous for F508del and a minimal function mutation (F/MF) and 67 homozygous for F508del (F/F) were enrolled in this study. Treatment with ETI improved the median (interquartile range (IQR)) LCI in F/MF (−1.0 (−2.0– −0.1); p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMagnetic Resonance ImagingAminophenolsQuinolonesIndolesBenzodioxolesLungAllelesPyrazolesCystic Fibrosis Transmembrane Conductance RegulatorHumansChildFemaleMaleProspective StudiesDrug CombinationsMutationPyridinesPyrrolidinesHomozygote

Substanzen

AminophenolsQuinolonesIndolesBenzodioxolesPyrazolesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsPyridineselexacaftorivacaftor

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitä…
  • Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany.
  • M. Stahl, M. Dohna, S.Y. Graeber and O. Sommerburg contributed equally as first authors.
  • Department for Radiology, Hannover Medical School, Hannover, Germany.
  • Division of Pediatric Pulmonology and Allergy, and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg, Heidelberg, Germany.

ORCID-Profile: Mirjam Stahl, Simon Y Graeber, Olaf Sommerburg, Katharina Schütz, Stephanie Thee, Jobst Röhmel, Mark O Wielpütz, Burkhard Tümmler, Marcus A Mall, Anna-Maria Dittrich

Förderung

  • German Federal Ministry of Education and Research
  • Deutsche Forschungsgemeinschaft
  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Stahl, M., Dohna, M., Graeber, S. Y., Sommerburg, O., Renz, D. M., Pallenberg, S. T., Voskrebenzev, A., Schütz, K., Hansen, G., Doellinger, F., Steinke, E., Thee, S., Röhmel, J., Barth, S., Rückes-Nilges, C., Berges, J., Hämmerling, S., Wielpütz, M. O., Naehrlich, L., …, & Dittrich, A. M. (2024). Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. European Respiratory Journal, 64(3), 2400004. https://doi.org/10.1183/13993003.00004-2024

Vancouver

Stahl M, Dohna M, Graeber SY, Sommerburg O, Renz DM, Pallenberg ST, et al. Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. European Respiratory Journal. 2024;64(3):2400004. doi:10.1183/13993003.00004-2024

BibTeX
@article{Stahl2024,
  author = {Stahl, Mirjam and Dohna, Martha and Graeber, Simon Y and Sommerburg, Olaf and Renz, Diane M and Pallenberg, Sophia T and Voskrebenzev, Andreas and Schütz, Katharina and Hansen, Gesine and Doellinger, Felix and Steinke, Eva and Thee, Stephanie and Röhmel, Jobst and Barth, Sandra and Rückes-Nilges, Claudia and Berges, Julian and Hämmerling, Susanne and Wielpütz, Mark O and Naehrlich, Lutz and Vogel-Claussen, Jens and Tümmler, Burkhard and Mall, Marcus A and Dittrich, Anna-Maria},
  title = {Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {3},
  pages = {2400004},
  doi = {10.1183/13993003.00004-2024}
}
Kostenlos starten →